



### **Driving Towards a Novel Neuroblastoma Clinical Trial**

The team has made significant progress over the past year as they remain focused on developing personalized immunotherapies and treatments. These therapies work by making neuroblastoma tumors visible to the immune system.

One line of research involves inhibiting the Myc oncogene with small-molecule drugs and combatting tumors with patients' own T-cells. The team has brought this research from bench to bedside over the course of 2022. Recently, they tested samples from non-Myc amplified stage-four neuroblastoma patients using techniques discovered in the laboratory. The results are promising and illustrate that the patient's own immune cells can be trained and activated against the tumor.

Another key milestone includes the development of ApoE antibodies to enhance the immune response in patient tumor cells and blood. This will pave the way for collaboration with the Good Medical Practices facility to launch an Investigational New Drug (IND) clinical trial protocol. We anticipate this trial will incorporate all three of the lab's strategies: suppressing the Myc-oncogene and blocking the ApoE checkpoint to render the tumor vulnerable to the immune system as well as leveraging CD24Fc fusion protein to protect the patient's surrounding healthy cells. The next steps will be trial recruitment after securing institutional review board and FDA approval.